晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展

doi:10.11904/j.issn.1002-3070.2022.05.013

Abstract

Abstract: Non-small cell lung cancer(NSCLC)is the most common histological type of lung cancer,which is mostly diagnosed at advanced stage and has a high mortality.The application of immune checkpoint inhibitors(ICIs)has significantly improved the 5-year survival rate of patients with advanced NSCLC,but while bringing survival benefits,it also leads to adverse events that are different from traditional treatment regimens,namely immune-related adverse events(irAEs).In recent years,the correlation between irAEs and clinical efficacy of ICIs has become a research hotspot.This article reviews the research progress on the correlation between irAEs and the efficacy of immunotherapy in advanced NSCLC.

Key words: Immune checkpoint inhibitors, Immune-related adverse events, Efficacy, Non-small cell lung cancer

CLC Number:

R730.51

LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer[J]. Journal of Practical Oncology, 2022, 36(5): 463-467.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.05.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I5/463

References

1 Relli V,Trerotola M,Guerra E,et al.Abandoning the notion of non-small cell lung cancer[J].Trends Mol Med,2019,25(7):585-594.
2 Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J].New Engl J Med,2015,373(17):1627-1639.
3 Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].New Engl J Med,2016,375(19):1823-1833.
4 Glode AE,May MB.Immune checkpoint inhibitors:significant advancements in non-small cell lung cancer treatment[J].Am J Health Syst Pharm,2021,78(9):769-780.
5 Aso M,Toi Y,Sugisaka J,et al.Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer[J].Oncologist,2020,25(3):e536-e544.
6 Cortellini A,Chiari R,Ricciuti B,et al.Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients[J].Clinical Lung Cancer,2019,20(4):237-247.
7 Haratani K,Hayashi H,Chiba Y,et al.Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer[J].JAMA Oncol,2018,4(3):374-378.
8 Hosoya K,Fujimoto D,Morimoto T,et al.Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors[J].Clin Lung Cancer,2020,21(4):e315-e328.
9 Naqash AR,Ricciuti B,Owen DH,et al.Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab:a pooled exploratory analysis from a global cohort[J].Cancer immunol immun,2020,69(7):1177-1187.
10 Ricciuti B,Genova C,De Giglio A,et al.Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab:long-term outcomes from a multi-institutional analysis[J].J Cancer Res Clin Oncol,2019,145(2):479-485.
11 Morimoto K,Yamada T,Takumi C,et al.Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy:a retrospective study[J].Front Oncol,2021,11:630136.
12 Berner F,Bomze D,Diem S,et al.Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer[J].JAMA Oncol,2019,5(7):1043-1047.
13 Zhou C,Chen G,Huang Y,et al.A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic non-squamous non-small cell lung cancer[J].J Thorac Oncol,2019,14(10 Suppl):215-216.
14 Osorio J,Ni A,Chaft J,et al.Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J].Ann Oncol,2017,28(3):583-589.
15 Kim HI,Kim M,Lee SH,et al.Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer[J].Oncoimmunology,2017,7(1):e1375642.
16 Owen DH,Wei L,Bertino EM,et al.Incidence,risk factors,and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer[J].Clin Lung Cancer,2018,19(6):e893-e900.
17 Peiro I,Palmero R,Iglesias P,et al.Thyroid dysfunction induced by nivolumab:searching for disease patterns and outcomes[J].Endocrine,2019,64(3):605-613.
18 Grangeon M,Tomasini P,Chaleat S,et al.Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer[J].Clin Lung Cancer,2019,20(3):201-207.
19 Cheung YM,Wang W,McGregor B,et al.Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors:a systematic review and meta-analysis[J].Cancer Immunol Immunother,2022,71(8):1795-1812.
20 Zhou N,Velez MA,Bachrach B,et al.Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC[J].Lung Cancer,2021,161:34-41.
21 Campredon P,Mouly C,Lusque A,et al.Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer:retrospective study of 105 patients[J].Presse Med,2019,48(4):e199-e207.
22 Ahn BC,Pyo KH,Xin CF,et al.Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice[J].J Cancer Res Clin Oncol,2019,145(6):1613-1623.
23 Fujimoto D,Yoshioka H,Kataoka Y,et al.Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer:a multicenter retrospective cohort study[J].Lung Cancer,2018,119:14-20.
24 Fukihara J,Sakamoto K,Koyama J,et al.Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors[J].Clin Lung Cancer,2019,20(6):442-450.
25 Sugano T,Seike M,Saito Y,et al.Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer[J].Thoracic Cancer,2020,11(4):1052-1060.
26 Ono K,Ono H,Toi Y,et al.Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer[J].Cancer Medicine,2021,10(14):4796-4804.
27 Sato K,Akamatsu H,Murakami E,et al.Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab[J].Lung Cancer,2018,115:71-74.
28 Shankar B,Zhang J,Naqash AR,et al.Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer[J].JAMA Oncol,2020,6(12):1952-1956.
29 Zhang Q,Wang W,Yuan Q,et al.Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer:systematic review and meta-analysis[J].Cancer Chemother Pharmacol,2022,89(1):1-9.
30 Teraoka S,Fujimoto D,Morimoto T,et al.Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab:a prospective cohort study[J].J Thorac Oncol,2017,12(12):1798-1805.
31 Judd J,Zibelman M,Handorf E,et al.Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors[J].Oncologist,2017,22(10):1232-1237.
32 D'arienzo PD,Olsson-Brown AC,Sallam M,et al.Immune-related toxicities in NSCLC:real-world experience from a tertiary cancer center[J].Ann Oncol,2019,30:26-27.
33 Viaud S,Saccheri F,Mignot G,et al.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J].Science,2013,342(6161):971-976.
34 Chaput N,Lepage P,Coutzac C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J].Ann Oncol,2017,28(6):1368-1379.
35 Kang J,Bluestone J,Young A.Predicting and preventing immune checkpoint inhibitor toxicity:targeting cytokines[J].Trends Immunol,2021,42(4):293-311.
36 Milano G,Innocenti F,Ciccolini J.The association between adverse events and outcome under checkpoint inhibitors:Where is the deal? [J].Transl oncol,2021,14(1):100952.

[1]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[2]	LIAN Xiaomin, MA Feng, ZHAO Lixia, MENG Wei, ZHAO Dandan, ZHAO Junfeng. Clinical comparative analysis of PD-1 inhibitor combined with anti-angiogenic drugs and chemotherapy in the second-line treatment of advanced lung adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(4): 339-345.
[3]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[4]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[5]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[6]	ZHANG Yiyi, LI Qi, LIU Xu, WANG Yanan, ZOU Yuanjie, ZHOU Huihui, XU Chunyan, SU Shengqi, GE Xin, WANG Tong. Analysis of 5-year survival and its influencing factors of patients with cervical cancer [J]. Journal of Practical Oncology, 2022, 36(1): 7-13.
[7]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[8]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[9]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[10]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[11]	HAN Shuling, YAO Yang, LIU Chao, ZHANG Yanqiao. Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(5): 476-479.
[12]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[13]	WANG Junmei, PAN Huiqing, LI Jingyi, JIA Di, ZHAO Weiming, LV Changlian. The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma [J]. Journal of Practical Oncology, 2021, 35(3): 243-247.
[14]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[15]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.

Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments